ArticleAAPS PharmSciTech2026
Fabrication of Second-Generation Acalabrutinib Nanocrystals by Employing the Nano-Edge Method for Improving the Physico-Chemical Properties and Forecasting their In-Silico Pharmacokinetic Behaviour.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acalabrutinib (ACL) is approved by the USFDA and classified as a BCS class II drug, primarily used for treating chronic lymphocytic leukaemia. It is characterised by low solubility, particularly at higher pH levels, which results in reduced systemic absorption. Our current research aims to repurpose ACL for breast cancer treatment by enhancing its solubility and overall bioavailability through a second-generation nanocrystal formulation (SGACNCs). SGACNCs were prepared using the Nano-Edge method, which combines microprecipitation and high-pressure homogenization. The prepared SGACNCs with a mean particle size of 250.5 ± 17nm were characterised by solid-state techniques such as FTIR, DSC, PXRD, SEM, and BET analysis. In vitro dissolution studies indicated that at pH levels of 6.8 and 7.4, there was a 99 ± 0.2% and 99 ± 0.1% release after 6 h, respectively. Furthermore, the apparent permeability of the SGACNCs were observed to be two times greater than that of ACL. The stability studies indicated that the SGACNCs remained stable for 3 months at 5 ± 3 °C. Gastroplus 10.1 software was utilized to predict the pharmacokinetic profiles of SGACNCs based on their in vitro dissolution characteristics. In vitro biological studies on MDA-MB-231 cell lines showed a 1.55-fold reduction in IC
Indexed as
Identifiers
41540286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.